Skip to content
MarketScale
‹ Back to IndustriesSciences

Do Standing Desks Really Help You Lose Weight?

Short answer: Yes. But it might take a while. According to a new research review just published by the European Journal of Preventative Cardiology, using a standing desk for six hours per day burns 54 more calories than sitting at a desk. While this may sound like a pretty underwhelming number, over the course of…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences ·
Share
Do Standing Desks Really Help You Lose Weight?

Key takeaways

01

According to a new research review just published by the European Journal of Preventative Cardiology, using a standing desk for six hours per day burns 54 more calories than sitting at a desk.

02

While this may sound like a pretty underwhelming number, over the course of…

Short answer: Yes. But it might take a while.

According to a new research review just published by the European Journal of Preventative Cardiology, using a standing desk for six hours per day burns 54 more calories than sitting at a desk. While this may sound like a pretty underwhelming number, over the course of four years, those calories add up to a potential reduction in weight of 22 pounds—which has got to be good for going down at least one or two pants sizes.

Researchers led by Dr. Farzane Saeidifard from the Division of Preventive Cardiology, in the Department of Cardiovascular Medicine at the Mayo Clinic looked through almost 700 scientific studies that sought to measure the health benefits of standing desks, and included 46 of them—the most rigorous of the collection—their review. These studies only measured sitting versus standing and looked at 1,184 standing desk users. Saeidifard and his team concluded that the difference in energy expenditure between standing desk users and sitting desk users—with no increase in caloric intake—would reduce body fat mass by 2.5 kg per year.

And the good news doesn’t stop with weight loss. Standing desks can help desk-bound folks move around more in general throughout the day, burning additional calories to compound the effect of the desk set-up alone. Standing desks, say experts, can also help prevent back pain associated with prolonged periods of sitting.

Ultimately, the researchers found, that “the substitution of sitting with standing could be a potential solution for a sedentary lifestyle to prevent weight gain in the long term,” and recommended that “future studies should aim to assess the effectiveness and feasibility of this strategy.”

The study also pointed out that population-based studies have reported the daily sitting time ranging from 3.2 to 6.8 hours (20–43% of adults’ waking hours) across 32 European countries. In the U.S., it’s more than 7 hours per day. So, implementing a standing desk into our workday is probably a good idea. Sitting all day isn’t just making us a little chubby. Sedentary behavior, expressed mainly as extended sitting time, has been blamed as one of the contributors to the high prevalence of cardiovascular disease and diabetes.

In other words? It’s time to elevate those desks, America!

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512